Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acrivon Therapeutics, Inc. (ACRV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Acrivon is a clinical stage biopharmaceutical company focused on precision oncology medicines developed using its Generative Phosphoproteomics AP3 platform, and its filings offer additional context on financial results, clinical programs, and business updates.
Among the documents available for ACRV are current reports on Form 8-K, which Acrivon uses to furnish press releases announcing quarterly financial results and to provide Regulation FD disclosures. For example, the company has filed 8-K reports to attach earnings press releases summarizing research and development expenses, cash and investment balances, and narrative business highlights, as well as to furnish a corporate presentation describing AP3 capabilities, synergy data for ACR-368 and ACR-2316 with immune checkpoint inhibitors, and updates to its pipeline overview.
Through this page, users can track how Acrivon reports its progress with lead programs such as ACR-368, a CHK1/CHK2 inhibitor in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, along with AP3-driven preclinical initiatives. Real-time updates from EDGAR ensure that new ACRV filings, including additional 8-Ks and other periodic reports, are reflected as they become available.
Stock Titan’s interface is designed to pair these filings with AI-powered summaries that explain the key points of each document in clear language. Users can quickly see what each ACRV filing covers—such as financial condition, clinical data highlights, or platform developments—while retaining the ability to open the full SEC text for detailed review, including any exhibits like press releases or corporate presentations incorporated by reference.
Acrivon Therapeutics, Inc. reported an insider equity transaction by its Chief Development Officer. On 11/14/2025, 403 shares of Acrivon Therapeutics common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being an open-market sale. Following this withholding event, the officer beneficially owned 15,283 shares of Acrivon Therapeutics common stock, held directly.
Acrivon Therapeutics, Inc. reported a routine insider equity transaction by its Chief Operating Officer. On 11/14/2025, 613 shares of Acrivon common stock were withheld at a price of $2.24 per share to cover mandatory tax withholding when restricted stock units vested. After this tax-related withholding, the officer beneficially owns 65,308 shares of Acrivon common stock in direct ownership. The filing is administrative in nature and reflects standard equity compensation and tax settlement practices for a senior executive.
Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions. On 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 shares of common stock withheld by the company at $2.24 per share to cover mandatory tax withholding upon vesting of restricted stock units, leaving him with 2,066,675 shares held directly. On the same date, 490 shares were similarly withheld at $2.24 per share from holdings reported as indirect, leaving 314,706 shares held indirectly. The filing notes that Dr. Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson are spouses and each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.
Acrivon Therapeutics (ACRV) reported Q3 2025 results, highlighting continued investment in its precision oncology programs. The company posted a net loss of $18.2 million for the quarter, improving from $22.4 million a year ago, as research and development expense decreased to $13.6 million (from $18.9 million). General and administrative expense was $6.0 million. Basic and diluted net loss per share was $0.47.
For the nine months ended September 30, net loss was $58.9 million, with operating cash use of $48.4 million. Acrivon ended the quarter with cash, cash equivalents and investments of $134.4 million, which management states is sufficient for at least 12 months and supports a projected runway into the second quarter of 2027.
Pipeline progress continued. The registrational‑intent Phase 2 trial of ACR‑368 in endometrial cancer previously reported a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature‑positive patients. The ACR‑368 OncoSignature test has FDA Breakthrough Device designation, and ACR‑368 holds Fast Track status. ACR‑2316, a WEE1/PKMYT1 inhibitor, is in Phase 1 with initial signs of activity, including a confirmed partial response at dose level 3. As of November 7, 2025, shares outstanding were 31,555,126.
Acrivon Therapeutics, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025, and business updates. The press release is included as Exhibit 99.1 dated November 13, 2025.
The company states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other SEC filings.
Acrivon Therapeutics (ACRV) insider activity: The Chief Legal Officer reported a routine tax-withholding event tied to restricted stock unit vesting. On 10/17/2025, a Form 4 shows transaction code F, where 558 shares of common stock were withheld by the issuer at $1.81 to satisfy mandatory taxes. After this administrative transaction, the officer directly beneficially owns 34,739 shares.
Mirza Mansoor Raza, the company Chief Medical Officer, reported acquiring 225,000 stock options in Acrivon Therapeutics, Inc. (ACRV) on 10/01/2025. The options carry an exercise price of $1.81 and are reported as acquired (Transaction Code A), leaving the reporting person with 225,000 derivative securities beneficially owned following the transaction. The filing states vesting terms: 25% vests on November 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a non-derivative disposition on 10/01/2025. The filing shows 284 shares of common stock were disposed at a price of $1.81 per share. The form states the shares were withheld by the issuer to satisfy mandatory tax withholding upon the vesting of restricted stock units. After the reported transaction, Ms. Miller beneficially owns 35,297 shares, held directly. The Form 4 was signed by attorney-in-fact Adam D. Levy on 10/03/2025.
Acrivon Therapeutics, Inc. furnished a corporate presentation on its website, providing an update on its business and research programs. The presentation includes new syngeneic mouse model data showing continued strong synergy between its clinical candidates ACR-368 and ACR-2316 and immune checkpoint inhibitors. After multiple rounds of tumor implantation over almost one year, the models showed complete tumor regression and evidence of immune memory, and the company further analyzed which immune cell types drive this effect. These results support the rationale for potential combinations of ACR-368 and ACR-2316 with anti-PD(L)1 agents in the front line setting. The company also updated its pipeline overview to include the all-comer ACR-368 + ULDG ARM 3 of the ongoing ACR-368-201 trial and expanded information on its Generative Phosphoproteomics AP3 platform. The presentation is attached as Exhibit 99.1.
Acrivon Therapeutics insiders reported an internal share disposition related to restricted stock unit vesting. On 08/21/2025, President and CEO Dr. Peter Blume-Jensen had 19,905 common shares dispositioned at $1.32 per share; the filing states these shares were withheld by the issuer to satisfy mandatory tax withholding on vested restricted stock units. After the transaction Dr. Blume-Jensen is reported to beneficially own 2,126,440 shares (direct). The filing also shows 315,196 common shares held indirectly by EVP Dr. Kristina Masson. Both reporting persons are officers and directors and are spouses; each disclaims beneficial ownership of the other’s holdings except to the extent of pecuniary interest. The Form 4 is signed by an attorney-in-fact on behalf of both reporting persons.